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controls based on age, gender, and hospital region. RESULTS: The 2006 NIS con-
tained a total of 15,748 unweighted hospital inpatient stays with pulmonary surgery, 
2,412 of which included an air leak and 13,336 were non-air leak stays. Patients with 
pulmonary surgery stays including an air leak were older than those patients without 
an air leak (61.5 yrs vs. 60.2 yrs; p = 0.0002), were less likely to be from the Northeast 
(17.3% vs. 21.52%, p < 0.0001) and more likely to be from the South (44.9% vs. 
41.9%, p = 0.0010). Multivariate regressions (N = 15,748) yielded incremental LOS, 
total charges and odds of in-hospital mortality due to the presence of an air leak of 
3.5 days (SE = 0.15), $14,272 ($1,198.2), and +26.0% (95% CI:-0.34%, 64.2%), 
respectively. The 1:1 case-control matching approach (N = 2,364 matched pairs) 
yielded differences in LOS, total charges and odds of in-hospital mortality of 3.6 days 
(0.14), $14,011 ($1,207.8) and +17.2% (−0.17%, 66.2%), respectively. CONCLU-
SIONS: In evaluating differences in health outcomes in a U.S. hospital inpatient 
database, adjusting for covariates using a matching scheme yielded only a modest 
impact vs. multivariate regression analysis.
SYSTEMIC DISORDERS/CONDITIONS – Clinical Outcomes Studies
PSY1
CONCORDANCE IN PATIENT REPORTED MEASURES OF OPIOID-
RELATED SIDE EFFECTS COLLECTED FROM CHECKLIST VERSUS 
OPEN-TEXT FORMAT QUESTIONS
Abouzaid S1, Benson C2, Chow W2, Kim M2
1Ortho-McNeil Janssen Scientiﬁc Affairs, LLC, Titusville, NJ, USA, 2Ortho-McNeil Janssen 
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OBJECTIVES: Compare two different formats—checklist and open text— of ques-
tions soliciting opioid-related side effects (OSEs) with respect to the proportion of 
patients reporting OSEs and the number of OSEs reported. METHODS: Data from 
Day 3 assessment of the oxycodone IR users registry (OUR), an ongoing, prospective, 
multicenter registry of patients age 18–85 with acute episodes of non-malignant pain 
requiring treatment with oxycodone IR for >5 days were used. Patients who completed 
two types of OSEs assessments on Day3 were included in the analysis. The ﬁrst assess-
ment is in an open-text format allowing for identiﬁcation of up to 7 symptoms. The 
second is in a checklist format listing 14 symptoms along with questions about the 
frequency and degree of distress associated with each. Correspondences between 
patient responses solicited through the two different formats were examined using 
descriptive statistics. Interim data were used for the current analysis. The entire registry 
patient population will be analyzed in early 2010. RESULTS: Among 182 patients 
examined for this analysis, mean (±SD) age was 49.3 (±12.7) years, 60.2% were female 
and 74.3% white. Oxycodone IR was most commonly prescribed for injury/trauma 
(30.5%), back/neck pain (28.8%), and arthritis (18.1%). The proportion of patients 
reporting any OSEs in the checklist was nearly two-fold that in the open text (98.9 
vs 53.6%; p < 0.001). Patients, on average, reported 4.1 (SD = 6.3) OSEs on the 
checklist vs 1.3 (SD = 1.6) on the open-text question (p < 0.001). Signiﬁcantly more 
events were reported in the checklist vs open text question for each OSE examined (p 
< 0.001). OSEs reported to be frequent and bothersome on the checklist were signiﬁ-
cantly more likely to appear in the open text compared to infrequent and mild 
symptoms. CONCLUSIONS: Frequency and extent of OSE reporting may vary by the 
format of questions administered. Caution is warranted in collecting, reporting, and 
comparing symptom data from different studies.
PSY2
PREDICTORS OF OBESITY MEDICATION USE IN AMBULATORY 
SETTING: NAMCS 2006–07 ANALYSIS
Mehta H, Parikh R, Patel J, Abughosh S
University of Houston, Houston, TX, USA
OBJECTIVES: To determine the independent predictors of prescription of anti-obesity 
medication for adult patients diagnosed with obesity and to determine association of 
insurance status on anti-obesity medication prescription. METHODS: The data source 
was 2006 and 2007 National Ambulatory Medical Care Survey, a national survey of 
U.S. non-institutionalized population. All adult patients >= 18 years diagnosed with 
obesity (ICD-9-CM: 278.00) were included in the study for analysis. Weighted descrip-
tive analysis and multivariate logistic regression were carried out to identify patterns 
of drug use and independent predictors of at least one prescription of anti-obesity 
medication, adjusting for age, race, sex, region, insurance status, co-morbidity, coun-
seling and MSA. RESULTS: An estimated 113 million adult visits had diagnosis of 
obesity in the 2 years. Of these, 5.79% visits resulted in anti-obesity medication 
prescription. In multivariate model, males (OR—0.244 CI: 0.128–0.463), were less 
likely to receive anti-obesity medication prescription as compared to females. Patient 
visits covered by private or public insurance were less likely to receive prescription 
(OR—0.056 CI: 0.021–0.146 and OR—0.080 CI: 0.034–0.189 respectively). Increase 
in age was associated with decreased (OR—0.976 CI: 0.962–0.990) likelihood of 
receiving anti-obesity medication prescription. Adults who received obesity counseling 
were almost four times more likely to receive anti-obesity medication prescription 
(OR—3.730 CI: 1.878–7.407). Physician type, MSA, co-morbidity status, race and 
region were not signiﬁcantly associated in the ﬁnal multivariate model. CONCLU-
SIONS: Study ﬁnding suggests that adequate coverage for anti-obesity medications 
might not be available for obese adults. Obesity is a harbinger for other chronic 
diseases like CHF, diabetes, hypertension, arthritis and some cancers; thus reducing 
access to obesity medications might lead to an overall increase in the health care 
expenditure in United States. Obesity counseling seems to promote medication use 
which might be due to an increased awareness among obese patients.
PSY3
CENTRAL VENOUS LINE INFECTIONS IN PATIENTS WITH 
HEMOPHILIA AND HOME CARE SERVICES
Tankersley MA1, Blankenship CS2, Doedyns A2, Lewis N2, Johnson N3, Tang J1
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OBJECTIVES: Patients with hemophilia require frequent administration of intrave-
nous clotting factor to prophylactically or episodically control bleeding from injury 
or activity. Severe patients may require the placement of a central venous access device 
due to the frequency of infusions or poor peripheral venous access. Subsequent central 
venous line infections are potentially life threatening and may require hospitalization 
which consumes excessive health care resources. Catheter infection events cost up to 
$29,000 per episode for acutely ill patients and can be much higher when cost of 
clotting factor is included. Costs of these events include intravenous antibiotics and 
device replacement. The study purpose was to evaluate incidence of central venous 
access device infections in people receiving clotting factor in the home setting. 
METHODS: A retrospective, longitudinal analysis of patients receiving intravenous 
clotting factor using data from the Accredo electronic medical record was conducted. 
Inclusion criteria were the presence or placement of a central venous access device and 
the dispensing of at least one clotting factor prescription during the study period. 
Patients were followed from October 1, 2008 through September 30, 2009. The 
patient reported infection rate was deﬁned as the number of bloodstream infections 
per 1000 patient catheter days. RESULTS: The sample size of 475 patients reviewed 
encompassed 131,916 patient catheter days during the study period with average 
catheter dwell time of 278 days. The central line infection rate was 0.53 per 1000 
patient catheter days with minimal month to month variation. CONCLUSIONS: 
Intravenous administration of clotting factor via a central venous access device is an 
important alternative infusion option for select patients with bleeding disorders. 
Patients can be well managed in the home on intravenously administered factor via 
central venous access devices. This is an important contribution to limited literature 
on central line infections in the home setting.
PSY4
DAILY AVERAGE CONSUMPTION ANALYSIS OF LOW BACK PAIN AND 
OSTEOARTHRITIS PATIENTS USING OXYMORPHONE EXTENDED 
RELEASE AND OXYCODONE HYDORCHLORIDE CONTROLLED 
RELEASE TABLETS IN A COMMERCIALLY INSURED POPULATION
Berner T, Puenpatom A, Lai PC, Thomson H, Hartry A
Endo Pharmaceuticals, Chadds Ford, PA, USA
OBJECTIVES: This study assessed the daily average consumption (DACON) patterns 
for oxymorphone extended release tablets and oxycodone hydrochloride controlled 
release tablets in the treatment of low back pain (LBP) and osteoarthritis (OA). 
METHODS: Observational, retrospective study of a US commercially insured health 
plan cohort, which included pharmacy and medical claims for patients with ≥1 diag-
nosis of LBP and/or OA. Subjects with OA and or LBP were identiﬁed by ICD-9-CM 
codes following classiﬁcations1,2,3 previously employed. The primary outcome measure 
for the analysis was DACON which was calculated by dividing the total number of 
tablets dispensed by the total number of days supply for equianalgesic4 doses of each 
medication, as deﬁned by an oxymorphone ER : oxycodone HCl CR ratio of 1:2. 
Patient demographic data were assessed and outcomes were stratiﬁed by age, gender, 
and region comparing users who had claim activity for 2 or more of the two medica-
tions for at least 30 days prior to and 90 days after the index date. The t-test was 
used to compare mean differences between the two populations for continuous vari-
ables. Multivariate analysis was conducted as a sensitivity analysis in controlling for 
age, gender, and region heterogeneity. RESULTS: Data analyzed encompassed 
approximately 25 million covered lives for the period January 2006 to March 2009. 
DACON across all tablet strengths for oxymorphone ER was 2.2 compared to 2.6 
for oxycodone CR (p < 0.01). For each formulations maximum strength tablet, oxy-
morphone ER 40 mg DACON was 2.6, compared to 3.7 for oxycodone CR 80 mg 
(p < 0.01). All statistically signiﬁcant results for patients with LBP and/or OA had 
higher DACONs for oxycodone CR than for oxymorphone ER. CONCLUSIONS: 
These ﬁndings imply that health plan drug policies may need to take into consideration 
overall usage patterns, patient demographics, and medical diagnoses for long-acting 
opioids in addition to tablet costs when making formulary decisions.
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A META-ANALYSIS OF EFFICACY AND SAFETY OF PARECOXIB IN 
ORTHOPEDICS SURGERY
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OBJECTIVES: The aim of this study was to conduct a meta-analysis of randomized 
clinical trials (RCTs) to determine effectiveness and safety of parecoxib as an analgesic 
option for adult patients in orthopedics surgery. METHODS: All meta-analysis esti-
mations were performed with RCTs based on trials with similar parecoxib doses (20 
or 40 mg) and by type of comparator (placebo or other drugs). Effectiveness was 
assessed with patient global treatment evaluation, consuming rescue drug rate, pain 
intensity at 24 or 48 h after surgery and morphine consume after surgery; safety with 
the frequency and type of adverse events(AE). RCT were searched in December 2008 
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in Medline, EMBASE, International Pharmacological Abstracts and the Cochrane 
Collaboration. Two independent reviewers identiﬁed the abstracts, selected the full 
articles, and extracted the data. Odds ratios and weighted means differences were 
calculated. Random effects models were employed in the analyses with RevMan v.5.0 
software. RESULTS: A total of 1253 studies were reviewed and 10 trials were ﬁnally 
selected where parecoxib was assessed in hip, knee and spine surgeries, as well as 
bunionectomy. In 6/10 studies, parecoxib 40 mg showed a higher global treatment 
evaluation against placebo (OR 0.20; 95%CI 0.13–0.31) and improvements in the 
consuming rescue drugs rate (OR 0.18; 95%CI 0.07–0.47), as well as in cumulative 
morphine consumption, and pain intensity (p < 0.001). In three studies, parecoxib 
was as effective as ketorolac, paracetamol, metamizole or morphine. Frequency of AE 
was similar between parecoxib and placebo or other drugs. Parecoxib 20 mg showed 
less postoperative fever than placebo (OR 0.46; 95%CI 0.24–0.89). CONCLUSIONS: 
Parecoxib 40 mg is an effective and safe analgesic option during the ﬁrst hours of the 
postoperative period in orthopedic surgeries.
SYSTEMIC DISORDERS/CONDITIONS – Cost Studies
PSY6
IMPACT OF A PRIOR AUTHORIZATION FOR PREGABALIN ON HEALTH 
PLAN DRUG EXPENDITURES
Bazalo G1, Weiss RC2, Joshi AV3
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OBJECTIVES: The purpose of this study was to model the economic impact of a prior 
authorization (PA) requirement for pregabalin from a US health plan perspective. 
METHODS: An Excel-based model was developed to simulate two hypothetical 
scenarios: 1) A health plan in which a PA is placed on pregabalin, and 2) a health 
plan in which there is no PA. In both scenarios, a mix of brand and generic products 
based on secondary prescription data from IMS was assumed dispensed to patients 
who did not receive a pregabalin prescription or who were denied pregabalin in the 
PA process. PA rejection rates were obtained from a PBM database analysis. The 
pregabalin prescribing rate was set to 10.3% in both the PA and no PA scenarios, 
with a denial rate of 50% in the PA scenario. The model incorporated the drug 
wholesale acquisition cost (WAC) or the federal upper limit for generics, cost of PA 
administration (published literature), and copayments, in each scenario for a cohort 
of 1000 patients over a one-year period. Sensitivity analyses were carried out 
with various PA administration costs and product mixes for the pregabalin alternatives. 
RESULTS: The difference in costs between the two scenarios was 0.4% ($886,000 
for the PA scenario vs. $889,000 for the “no PA” scenario). Setting the PA administra-
tion cost to zero, the difference in drug acquisition costs alone was 0.8%. When the 
product alternatives to pregabalin were replaced with gabapentin only, the difference 
in drug acquisition costs alone was 3.4%. CONCLUSIONS: Based on the actual mix 
of products used across pregabalin indications, a PA on pregabalin has a minimal 
impact on total costs to the health plan. The difference in drug acquisition costs was 
less than 1% for a mix of product alternatives based on audited prescription data.
PSY7
ECONOMIC VALUE OF LIDOCAINE PATCH 5% VS. GABAPENTIN OR 
PREGABALIN IN MEDICAID PATIENTS WITH POST HERPETIC 
NEURALGIA
Ivanova JI1, Puenpatom RA2, Kirson NY3, Birnbaum HG3, Wei R3, Kantor E3, Summers K2
1Analysis Group, Inc., New York, NY, USA, 2Endo Pharmaceuticals, Inc., Chadds Ford, PA, 
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OBJECTIVES: Compare direct health care resource utilization and costs of post 
herpetic neuralgia (PHN) patients initiating lidocaine or gabapentin/pregabalin. 
METHODS: Patients with PHN diagnosis (ICD-9-CM: 053.12, 053.13 or 053.19) or 
herpes zoster diagnosis (ICD-9-CM: 053.0x, 053.10, 053.11, 053.2x, 053.7x-053.9x) 
and at least 30 days PHN-related treatment were identiﬁed from Medicaid claims data 
from Florida, Iowa, Missouri, and New Jersey, 1999–2007. Patients initiated mono-
therapy with lidocaine or gabapentin/pregabalin after PHN diagnosis, had continuous 
eligibility 6 months before (baseline) and 6 months after (study period) the medication 
index date, and were at least 18 years old. Lidocaine patients were matched to patients 
initiating gabapentin/pregabalin on age and propensity to initiate lidocaine based on 
baseline characteristics. Study period direct resource use and costs, calculated as 
reimbursements to providers for medical services and prescription drugs, were com-
pared between the two matched groups using univariate analysis. RESULTS: After 
matching on age and propensity to initiate lidocaine, baseline characteristics (such as 
age, comorbidities, prior resource use and direct costs) were well-balanced between 
the treatment groups. Matched patients were on average 61 years old, 73% were 
women, approximately 24% had a mental disorder diagnosis, and 55% had other 
painful conditions during the baseline period. Among matched lidocaine (n = 306) 
and gabapentin/pregabalin (n = 306) patients, there were no statistically signiﬁcant 
differences in study period treatment with tricyclic antidepressants (16.0% in both 
groups), analgesic medications (86.6% vs. 86.9%), and other PHN-related treatments 
(6.9% vs. 6.2%) such as DREZ lesions, epidural steroids and nerve blocks. No statisti-
cally signiﬁcant differences were found in resource use, average total health care costs 
per patient ($8,740 vs. $8,630, P = 0.880) and PHN-related costs ($1,046 vs. $1,067, 
P = 0.908) between matched lidocaine and gabapentin/pregabalin patients. CONCLU-
SIONS: PHN patients treated with lidocaine cost no more than patients treated with 
gabapentin or pregabalin over the 6-month study period.
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DECREASES HOSPITALIZATIONS IN PATIENTS WITH  
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OBJECTIVES: To assess maintenance treatment patterns of inﬂiximab (IFX) in ulcer-
ative colitis (UC) and the impact of persistence on UC-related hospitalization. 
METHODS: A retrospective claims analysis using the IMS LifeLinkTM Health Plan 
Claims Database between September 1, 2004 and March 31, 2009 was conducted. 
The index date was deﬁned as the ﬁrst claim for IFX between September 1, 2005 and 
January 1, 2008. Continuous enrollment for 12 months prior and 14 months after 
the index date was required. Patients were required to have ≥2 claims with an ICD-9 
diagnosis code for UC pre-index and be ≥18 years at index. Patients with selected 
other inﬂammatory diseases and those undergoing colectomy within 12 weeks of the 
index date were excluded. Patients with ≥1 infusion following day 56 post index were 
considered to have maintenance therapy. Hospitalizations were compared to the group 
of patients with induction infusions only. Within the maintenance treatment group, 
therapeutic persistence was deﬁned as a medication possession ratio (MPR) of ≥80%; 
this group was compared to those without therapeutic persistence (<80% MPR). 
RESULTS: A total of 420 patients were included in the analyses; mean (SD) age = 
43.9 (14.1) years; 47.9% female; mean (SD) 6.08 (2.49) IFX infusions; 84.3% (n = 
354) continued to maintenance therapy. Maintenance patients incurred fewer UC-
related hospitalizations (0.12 vs. 0.32), associated costs ($3118 vs. $8610) and had 
shorter average lengths of stay (ALOS; 8.9 vs. 11.65 days) than induction-only 
patients. Among maintenance patients, those demonstrating therapeutic persistence (n 
= 202; 57.1%) incurred fewer UC-related hospitalizations (0.03 vs. 0.22) and associ-
ated costs ($423 vs. $6678), and had shorter ALOS (6.67 vs. 9.71 days) than those 
without therapeutic persistence. CONCLUSIONS: Persistent maintenance treatment 
with IFX is associated with fewer UC-related hospitalizations, lower inpatient costs, 
and shorter ALOS among patients with UC. Physicians should monitor patients with 
UC to ensure appropriate IFX maintenance therapy paradigms are followed.
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OBJECTIVES: To quantify individual and national estimates of the direct costs of 
inﬂammatory bowel disease (IBD), Crohn’s disease (CD), and ulcerative colitis (UC), 
using national survey data. METHODS: This was a retrospective study using 1996–
2006 data from the Medical Expenditure Panel Survey (MEPS). Individuals self-
reported health conditions were mapped to the International Classiﬁcation of Diseases, 
9th Revision, Clinical Modiﬁcation (ICD-9-CM) diagnostic codes. Individuals with an 
ICD-9-CM diagnostic code of 555.x (CD) or 556.x (UC) were categorized as having 
IBD. Health care services included prescriptions, inpatient, outpatient, emergency 
room, ofﬁce, and home health services. Health care costs were collected for the health 
care services. Out-of-pocket (OOP) costs were the portion of individuals’ total pay-
ments for the health care services. To estimate the health care and OOP costs, an 
ordinary least squares model was performed. Individuals with and without IBD were 
compared. RESULTS: There were 411 individuals with IBD (mean age = 47.7 years; 
57% Female), and 161,953 individuals without IBD (mean age = 48.2 years; 58% 
Female). The annual per capita health care costs for individuals with IBD were more 
than double those for individuals without IBD ($11,759 vs. $5,700; p < 0.001). The 
annual per capita OOP costs for individuals with IBD were also almost twice those 
of individuals without IBD ($2,082 vs. $1,147; p < 0.001). When combining health 
care and OOP costs, IBD increases the total annual per capita direct costs by $7,021. 
The US national annual estimates of the health care, OOP, and total direct costs 
secondary to IBD are $2.8 billion, $0.4 billion, and $3.2 billion respectively. CON-
CLUSIONS: The direct costs associated with IBD are substantial not only to health 
care payers but to patients as well. The extent to which appropriate and early diagnosis 
and treatment of IBD reduce the total health care costs for individuals with this disease 
should be examined.
PSY10
THE DIRECT MEDICAL COSTS OF PSORIASIS: EVIDENCE FROM UNITED 
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OBJECTIVES: To quantify individual and national estimates of the direct medical 
costs of psoriasis (PsO) and similar disorders, using national survey data. METHODS: 
This was a retrospective study using 1996–2006 data from the Medical Expenditure 
Panel Survey (MEPS). Individuals’ self-reported current health conditions were 
mapped to International Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation 
(ICD-9-CM) diagnostic codes. Individuals with an ICD-9-CM diagnostic code of 696.
xx were categorized as having PsO. Health care services included prescriptions, inpa-
tient, outpatient, emergency room, ofﬁce, and home health services. Health care costs 
